Clinicopathological characteristics and prognostic analysis of PIK3CA mutation in breast cancer patients in Northwest China

• Published in: Pathology, research and practice research and practice, 2022-10, Vol.238, p.154063-154063, Article 154063
• Main Authors: Lv, Wei, Du, Chong, Zhang, Yinbing, Wu, Fei, Jin, Yaofeng, Chen, Xi, Liu, Xuan, Feng, Cong, Ma, Xingcong, Zhang, Shuqun
• Format: Article
• Language: English
• Subjects: Breast cancer; Northwest China; PIK3CA mutation; Prognosis; Targeted therapy
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2022.154063

Multiple studies on PIK3CA mutations in breast cancer (BC) had been performed, which showed the controversial results among different countries and races even those from the same country. The present study aimed to explore the PIK3CA gene mutation status in BC patients in Northwest China and reveal the relationship between PIK3CA mutations and clinicopathological features along with prognosis. 1002 BC patients from Northwest China were recruited in this study, genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissues, and hotspot mutations in the exon 9 and 20 of PIK3CA gene were detected by ARMS-PCR. PIK3CA mutations were found in 31.2% (313/1002) of BC patients, among them 66.1% were mutations in exon 20% and 32.6% were mutations in exon 9. H1047R was the most common mutation type, accounting for 56.5% of the total mutated samples. Significant correlations were observed between PIK3CA mutation status and age (P = 0.035), histopathologic types (P = 0.004), pathological grade (P = 0.013), ER positivity (P